Drug Approvals in 2022: A Recap of Notable FDA Regulatory Decisions

Fewer new drugs won FDA approvals in 2022 compared to previous years, but some of the products that passed regulatory muster are indicative of trends expected to continue into 2023. For example, more gene and cell therapies are on track to face regulatory decisions in the coming year.

Related Keywords

Japan ,United States ,American ,Sanofi Xenpozyme ,Behring Hemgenix ,Eli Lilly ,Amgen Lumakras ,American Society Of Hematology ,Amylyx Pharmaceuticals ,Johnson ,Bluebird Bio ,Biomarin Pharmaceutical ,Agios Pharmaceutical Pyrukynd ,Mirati Therapeutic Krazati ,Legend Biotech ,American Society ,Weight Loss ,Obesity ,Verweight ,Diabetes ,Massachusetts ,Medical Devices ,Startups ,Healthcare Innovation ,Medcity News ,San Francisco ,Life Sciences ,Accelerator ,Rock Health ,Startup Advice ,Startup Funding ,Patient Monitoring System ,Otion Sensors ,Dc ,Healthcare It ,Washington ,Foodborne Pathogens ,Iagnostics Company ,Iagnostic Platforms ,Minimally Invasive Surgery ,Aser Surgery ,Cambridge ,Dealflow ,Hospitals ,Wellpoint ,Ealthways ,Ealth And Wellness ,Mployee Wellness Programs ,Investing ,Wellness ,Medtronic ,Hanghai Innovation Center ,China ,R D ,Mdt ,Minneapolis ,Minnesota ,Publics ,Twin Cities ,Ulcerative Colitis ,Abbott Labs ,Humira ,Doctors ,Pharmaceuticals ,Skin Disorders ,D Anderson Cancer Center ,Cancer ,Texas ,Renal Denervation ,St Jude Medical ,Stj ,Emr ,Hr ,Electronic Health Records ,Electronic Medical Records ,Certified Emr ,Ehr ,Advanced Cellular Technology ,Amyotrophic Lateral Sclerosis ,Embryonic Stem Cells ,Geron Corporation ,Lou Gehrigs Disease ,Macular Degeneration ,Regenerative Medicine ,Spinal Cord Damage ,Value Based Healthcare System ,Obamacare ,Ee For Service Model ,California ,Cleveland ,Health Insurance ,Insurance ,Ohio ,Pennsylvania ,Politics ,Cancer Treatment Options Library ,Aetna ,Pet ,Aet ,Health It ,Phi ,Philadelphia ,Autoimmune Diseases ,Biopharma Nl ,Dancer ,Clinical Trials ,Fda ,Gene Therapy ,Rare Disease , ,